|[March 21, 2013]
Research and Markets: PharmaPoint: HIV - Italy Drug Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/2zpskr/pharmapoint_hiv)
has announced the addition of the "PharmaPoint:
HIV - Italy Drug Forecast and Market Analysis to 2022" report
to their offering.
GlobalData has released its new Country report, PharmaPoint: HIV - Italy
Drug Forecast and Market Analysis to 2022. Human Immunodeficiency Virus
(HIV), the causative agent of AIDS, has claimed millions of lives since
its emergence. However, the advent of antiretroviral therapy (ART) has
transformed the face of HIV/AIDS from a deadly disease to a manageable
chronic condition for most infected individuls. Antiretroviral
treatment not only reduces the viral load and reconstitutes immune
function, but also decreases infection incidence rates by limiting viral
The treatment algorithm in HIV has characteristically involved multiple
drug regimens designed to tackle the virus on different levels. In the
recent past, simplified dosing regimens through the emergence of single
tablet regimens (STRs) or fixed dose combination (FDC) therapies have
become increasingly popular amongst physicians and patients alike by
increasing clinical efficacy thresholds and enabling patient compliance.
Atripla was the first STR to enter Italy in 2008, and STRs have been the
focus of R&D ever since. ViiV Healthcare and Gilead Sciences are the
main companies pursuing STRs in order to position themselves as the
market leaders in Italy.
- Overview of Italy including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview on
the competitive landscape.
- Detailed information on the key drugs in Italy including product
description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Italy from 2012-2022.
- Analysis of the impact of key events as well the drivers and
restraints affecting Italy HIV market.
For more information visit http://www.researchandmarkets.com/research/2zpskr/pharmapoint_hiv
[ InfoTech Spotlight's Homepage ]